Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 3,534 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: ARDS (Acute Respiratory Distress Syndrome)
Interventions: HT31-1, Saline (0.9%, sterile, for infusion); Drug · Other
Lead sponsor: HTIC, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Degenerative Arthritis and Postoperative Pain
Interventions: Placebo, Gapabentin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Traumatic Brain Injury
Interventions: autologous bone marrow mononuclear cells, Placebo Infusion; Biological · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 5 Years to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona • Houston, Texas

Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions: Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more

Conditions: Postoperative Depression
Interventions: Ketamine, Normal saline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alcohol Use Disorder
Interventions: Ketamine, Saline; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple System Atrophy
Interventions: Amlenetug, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Francisco, California + 18 more

Conditions: Knee Osteoarthritis, Synovitis of Knee
Interventions: 4P004, Placebo (NaCl 0.9%); Drug
Lead sponsor: 4Moving Biotech; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Tucson, Arizona • Chicago, Illinois • Burlington, Massachusetts

Conditions: Discogenic Pain
Interventions: High yield pure PRP, Placebo, ProPlaz PPC; Device · Other
Lead sponsor: Neurological Associates of West Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Campbell, California • Santa Monica, California • Peachtree City, Georgia + 2 more

Conditions: Heart Diseases, Left Ventricular Dysfunction
Interventions: Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure; Drug · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 30 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Pain, Obesity, Hypoxia
Interventions: Ketamine, placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Migraine, Healthy
Interventions: Placebo; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 50 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Bacterial Infections
Interventions: XNW4107, Imipenem/Cilastatin, placebo; Drug
Lead sponsor: Evopoint Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Cardiovascular Diseases
Interventions: Fasudil Hydrochloride, Saline; Drug · Other
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Cold Induced Headache, Brain Freeze, Cold Induced Cephalgia, Headache
Interventions: Lidocaine Topical 4% Topical Solution, Bitrex, normal saline; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Uncontrolled Postoperative Pain
Interventions: 0.375% ROPIVACAINE, placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: FSHD - Facioscapulohumeral Muscular Dystrophy
Interventions: ULSC, Placebo; Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 15 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Treprostinil Inhalation Solution, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Well-Being, Psychological, Psychedelic Experiences
Interventions: Psilocybin, Saline Placebo, Clonidine; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: Unfractionated heparin (UFH), Bendavia, Saline (0.9%, sterile, for infusion); Drug
Lead sponsor: Mighty Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pain, Postoperative
Interventions: bupivacaine and epinephrine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Alcohol Use
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Blood Pressure, Hypertension
Interventions: Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Total Knee Arthroplasty (Postoperative Pain)
Interventions: ATX101, bupivacaine hydrochloride, saline placebo; Drug
Lead sponsor: Allay Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 11
States / cities: Little Rock, Arkansas • Tamarac, Florida • Atlanta, Georgia + 7 more

Search by objective public record fields.

Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS

Effect of Gabapentin on Orthopedic Pain

Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

Ketamine for the Treatment for Alcohol Use Disorder in the ED

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

Safety and Efficacy of PRP for Treatment of Disc Pain

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study

Molecular and Functional PET-fMRI Measures of Analgesia in Migraine

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

Red Blood Cell ATP Release and Vascular Function in Humans

Sphenopalatine Ganglion Block and Cold Induced Headaches

Can Post-operative TAP Block Improve Quality of Recovery After C-sections in Patients on Methadone Maintenance?

Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

Preemptive Local Anesthesia in Vaginal Surgery

Oxytocin, Alcohol Craving, and Intimate Partner Aggression

Reversing Glucose and Lipid-mediated Vascular Dysfunction

Phase 2B Study Assessing Pain Relief After Replacement of the Knee